$TLSI News

TriSalus Life Sciences to Host Third Quarter 2026 Financial Results Conference Call

Full Transcript: TriSalus Life Sciences Q2 2026 Earnings Call

TriSalus Secures FDA Clearance For TriNav Advance as Stock Tests Key Support

TriSalus Life Sciences Shares Rise 15.6% After FDA Clearance for TriNav Advance

HC Wainwright & Co. Maintains Buy on TriSalus Life Sciences, Raises Price Target to $12

TriSalus Life Sciences Receives FDA Clearance for TriNav® Advance, Strengthening Comprehensive Pressure-Enabled Drug Delivery™ (PEDD™) Portfolio for Liver Embolization

HC Wainwright & Co. Initiates Coverage On TriSalus Life Sciences with Buy Rating, Announces Price Target of $11

TriSalus Life Sciences to Participate in the H.C. Wainwright & Company 28th Annual Global Investment Conference

TriSalus Highlights Tumor-Treatment Expansion, FDA Catalyst at Growth Conference

TriSalus Life Sciences Q2 Earnings Call Highlights

TriSalus Life Sciences Inc (TLSI) (Q2 2026) Earnings Call Highlights: New CMS G-code Expands ...

TriSalus Life Sciences, Inc. (TLSI) Q2 2026 Earnings Call Transcript

TriSalus Life Sciences Reports Second Quarter 2026 Results

TriSalus Life Sciences Affirms FY2026 Sales Guidance of $54.000M-$57.000M vs $52.396M Est

TriSalus Life Sciences Q2 EPS $(0.16) Misses $(0.15) Estimate, Sales $11.407M Beat $10.267M Estimate

TriSalus Life Sciences to Participate in the Canaccord Genuity 46th Annual Growth Conference

TriSalus Life Sciences to Host Second Quarter 2026 Financial Results Conference Call

TriSalus Life Sciences to Host Virtual KOL Event on June 24 Featuring New Real-World Evidence for Pressure-Enabled Drug Delivery™ in Liver Cancer

Lake Street Maintains Buy on TriSalus Life Sciences, Lowers Price Target to $8

TriSalus Life Sciences Inc (TLSI) Q1 2026 Earnings Call Highlights: Strategic Expansion and ...